The ONCOTRACK ULTIMA Gene Panel is an advanced next-generation sequencing (NGS) test that analyzes 56 key theranostic genes associated with cancer development, progression, and treatment response. It helps identify actionable mutations that guide targeted therapies, immunotherapy suitability, and personalized cancer management. Using peripheral blood, it offers a minimally invasive liquid-biopsy approach for genetic tumor profiling. This panel supports early detection, risk assessment, and optimized therapeutic planning.
Price:
Rs. 49,400.00
Sample Type: PERIPHERAL BLOOD**
Fasting Not Required
Notes:O0041
Frequently Asked Questions (FAQ's):
1. What does the ONCOTRACK ULTIMA test analyze?
It studies 56 cancer-related genes to detect mutations that influence diagnosis, prognosis, and treatment choices.
2. Is this a blood-based test?
Yes, the test uses peripheral blood, offering a non-invasive alternative to tissue biopsy.
3. Who should take this test?
Patients diagnosed with cancer, those with suspected malignancy, or individuals needing targeted therapy insights.
4. Can this test guide treatment decisions?
Yes, it identifies actionable mutations that help oncologists choose targeted drugs or immunotherapies.
5. How soon are results available?
Turnaround time depends on the lab, typically 10–21 days for NGS panels.
6. Does it detect hereditary cancer risk?
It primarily evaluates somatic (tumor-related) mutations, though some hereditary variants may also be seen.
7. Is it useful for monitoring cancer?
Yes, liquid-biopsy-based panels can help track tumor evolution and treatment response over time.